Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alector, Inc. - Common Stock (NQ:ALEC)

1.450 -0.040 (-2.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alector, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT 
From Alector, Inc.
Via GlobeNewswire
This Texas Instruments Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
Alector Provides Executive Leadership Update
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Alector, Inc.
Via GlobeNewswire
Earnings Scheduled For February 26, 2025
 
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
Alector Reports First Quarter 2025 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Top movers in Thursday's after hours session
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease
From Alector, Inc.
Via GlobeNewswire
Alector Provides Executive Leadership Update
From Alector, Inc.
Via GlobeNewswire
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call
Call Scheduled for Wednesday, February 26, 2025, at 4:30 p.m. ET/1:30 p.m. PT 
From Alector, Inc.
Via GlobeNewswire
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
From Alector, Inc.
Via GlobeNewswire
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges. 
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30
Via Talk Markets
Topics Stocks / Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Crude Oil Moves Lower; Dick's Sporting Goods Earnings Top Views
 
Via Benzinga
Nasdaq Rises 100 Points; Abercrombie & Fitch Shares Fall After Q3 Results
 
Via Benzinga
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%. 
Via Benzinga
US Stocks Mixed; Best Buy Posts Downbeat Earnings
 
Via Benzinga
Leslie's Posts Weak Results, Joins Zoom Video And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
From Alector, Inc.
Via GlobeNewswire
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
From Alector, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.